ReviewJournal of translational medicine2025
A review of C/EBP α: a potential novel target for solid tumor intervention.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mammary adipocyte plasticity and epithelial crosstalk: roles in development, remodeling, and disease.Reviews in endocrine & metabolic disorders · 2026Review
- CEBPB emerges as a key regulatory factor in human cancers through diverse molecular mechanisms and clinical implications.Discover oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
C/EBPα (CCAAT enhancer binding protein) is a pivotal transcription factor with widespread expression in multiple tissues, including hematopoietic tissues, liver, lungs, mammary glands, skin, and adipose tissue. It plays a significant role in the developmental regulation of these tissues. Previous research has primarily concentrated on C/EBPα's involvement in the hematological system, particularly its role in maintaining human hematopoietic stem cell homeostasis and regulating myeloid differentiation. Notably, recent studies have revealed that C/EBPα is instrumental in the development and therapeutic targeting of solid tumors. Abnormal expression of C/EBPα has been observed in various tumor types, such as liver, breast, pancreatic, gastric, and lung cancers, where it regulates tumor cell proliferation, differentiation, and other processes through signaling pathways including EGFR/β-catenin, Wnt, and so on. Moreover, the expression levels of C/EBPα are closely associated with the clinical prognosis of these solid tumors. These findings suggest that C/EBPα may serve as a promising new target for clinical interventions against solid tumors. In this paper, we systematically review the structure, function, and expression regulation mechanism of C/EBPα. We also discuss its biological functions in solid tumors such as breast, liver, and pancreatic cancers, along with key scientific issues that need to be addressed in future studies, our aim is to provide new perspectives and robust support for the in-depth elucidation of the biological function of C/EBPα, and for the development of new strategies for the clinical treatment of solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.